In addition to antibodies, anti-CTLA-4 antibodies can significantly enhance CD4 and CD8 T cell immunity. This effect is observed even in PD-1− mice, indicating that the combination of anti-CTLA-4 and anti-PD-1 antibodies potentiates T cell immunity and augments the clinical activity of both antibodies.

**Summary**

- AGEN1884 (anti-CTLA-4, ip) and AGEN2034 (anti-PD-1) antibodies were discovered using Agener’s proprietary mammalian display antibody platform (Repertoire Display™).
- AGEN1884 and AGEN2034 have the ability to concurrently target CTLA-4 and PD-1 T cell checkpoint receptors.
- AGEN1884 combined with AGEN2034 significantly improved T cell responses compared to AGEN1884 alone.
- AGEN1884 combined with other antibodies targeting the PD-1 pathway (immunobodies and bispecific antibodies) significantly augmented T cell responses.
- AGEN1884 combined with other immune-modulatory antibodies targeting co-inhibitory and co-activation pathways to promote T cell responses, including the use of AGEN2034 in multiple clinical combinations.
- In addition to antibodies, AGEN1884 can be combined effectively with Agener’s proprietary tumor necrosis factor receptor-based AutoSynVax™ vaccine and enhanced both CD4+ and CD8+ T cell immunity.
- Preclinical data evaluating AGEN1884 in patients with advanced solid tumors have been initiated to evaluate safety and establish pharmacokinetic and pharmacodynamic (PD) parameters.
- Clinical studies to evaluate AGEN1884 in combination with AGEN2034 are planned, as well as AGEN1884 in combination with AutoSynVax™.